---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-048880"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:33:15.599242+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences appoints Teresa Bitetti to Board of Directors

## Summary
- Teresa Bitetti appointed as Class II director effective March 31, 2025, filling newly created vacancy.
- Bitetti is President of Global Oncology at Takeda; also appointed to Compensation Committee.
- Received initial stock option for 29,000 shares and RSU for 21,000 shares, vesting over 3 years.
- Board size increased from six to seven directors.

## SEC filing metadata
- accession: 0000950170-25-048880
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017025048880/0000950170-25-048880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017025048880/aura-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-048880
- JSON: https://secwatch.observer/filing/0000950170-25-048880.json
- Plain text: https://secwatch.observer/filing/0000950170-25-048880.txt

## Key facts
- Executive change
  Teresa Marie Bitetti was appointed as Class II Director at Aura Biosciences, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: unanimously appointed Teresa Marie Bitetti, MBA, as a Class II director, effective March 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017025048880/0000950170-25-048880-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.